• Proteasome Inhibition in Muscle Aging: MG-262 as a Translati

  2026-05-11

  This thought-leadership article explores the mechanistic and translational value of MG-262 (Z-Leu-Leu-Leu-B(OH)2) in dissecting skeletal muscle proteostasis, especially in the context of age-related decline in chaperone-mediated autophagy (CMA). Bridging foundational autophagy research and applied proteasome inhibition, we offer strategic guidance for experimental design, protocol optimization, and model selection. The piece differentiates itself by integrating recent high-impact findings, advanced applications, and workflow recommendations for translational researchers.

• MG-132 (Z-LLL-al): Proteasome Inhibition in Neurodegeneratio

  2026-05-11

  Explore the multifaceted roles of MG-132 in proteasome inhibition, with unique insights into its application for neurodegenerative and cancer research. Learn how recent discoveries on TDP-43 aggregation inform advanced assay design and therapeutic strategies.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Advanced Proteasome Inhibitio

  2026-05-10

  Explore the advanced utility of MG-262 (Z-Leu-Leu-Leu-B(OH)2) in dissecting proteasome function, muscle proteostasis, and age-related autophagy decline. This cornerstone article uniquely connects mechanistic detail with assay design and skeletal muscle biology.

• Otilonium Bromide: Applied Antimuscarinic Agent in Neuroscie

  2026-05-09

  Otilonium Bromide, a high-purity antimuscarinic agent from APExBIO, enables robust and reproducible modulation of cholinergic signaling in neuroscience and smooth muscle models. This article spotlights practical workflows, troubleshooting strategies, and protocol optimizations that empower researchers to harness its full investigative potential.

• FGF19 Drives NPC Angiogenesis via TRIM21-ANXA2 Ubiquitinatio

  2026-05-09

  This study reveals that FGF19 promotes nasopharyngeal carcinoma (NPC) progression by enhancing angiogenesis through the inhibition of TRIM21-mediated ANXA2 ubiquitination. The findings illuminate a novel FGF19–TRIM21–ANXA2 pathway, suggesting potential biomarkers and therapeutic targets for NPC angiogenesis and early metastasis.

• Y-27632: Selective ROCK Inhibitor for Cytoskeletal Modulatio

  2026-05-08

  Y-27632 is a selective ROCK inhibitor widely used to modulate cytoskeletal dynamics in cell biology research. It disrupts actin stress fiber formation by inhibiting ROCK1 and ROCK2 with high specificity. APExBIO's Y-27632 (SKU B1293) enables reproducible manipulation of Rho-associated kinase signaling for applications in stem cell differentiation and cancer biology.

• Moxidectin: Macrocyclic Lactone Anthelmintic & Antifungal Sy

  2026-05-07

  Moxidectin is a macrocyclic lactone anthelmintic with proven efficacy in parasitic worm control and emerging evidence for antifungal synergy. Its mechanism involves binding glutamate-gated chloride channels in parasites and elevating ergosterol biosynthesis in Candida albicans, potentiating polyene antifungals. High-purity moxidectin from APExBIO enables translational research across veterinary and antifungal domains.

• Erlotinib in Translational Oncology: Mechanisms, Models, and

  2026-05-07

  This thought-leadership article explores how Erlotinib (NSC 718781) advances translational cancer research by dissecting its mechanistic role as an EGFR tyrosine kinase inhibitor, integrating recent findings on SCUBE3-mediated oncogenic signaling, and providing strategic guidance on rigorous experimental design. With direct comparison to antibody-based SCUBE3 targeting, the article contextualizes Erlotinib’s value in both preclinical models and future translational pipelines. Protocol and assay guidance is backed by current literature and workflow recommendations, with a focus on reproducibility and the evolving competitive landscape.

• Nile Red (Nile Blue Oxazone): Precision Lipid Droplet Visual

  2026-05-06

  Nile Red (Nile blue oxazone) is a widely used lipophilic fluorescent dye for intracellular lipid droplet staining and lipid metabolism research. Its dual-emission properties enable selective and quantitative analysis of lipid storage dynamics in diverse cell types. APExBIO’s Nile Red (B8209) offers high specificity and robust performance for biomedical investigations.

• GRK Subtype Control of M1 Receptor Signaling Bias Deciphered

  2026-05-06

  This study elucidates how distinct GRK subtypes regulate biased signaling at the M1 muscarinic acetylcholine receptor (M1 mAChR), with a focus on the molecular mechanisms underlying selective G protein and β-arrestin engagement. The findings provide quantitative insight into how allosteric modulators such as Benzyl Quinolone Carboxylic Acid (BQCA) fine-tune acetylcholine receptor signaling, offering critical context for Alzheimer's disease research and cognitive function modulation.

• Cytokine and Glucocorticoid Control of BIRC2/3 in Lung Epith

  2026-05-05

  This study delineates the differential regulatory mechanisms governing BIRC2 and BIRC3 expression in pulmonary epithelial cells under inflammatory and glucocorticoid stimuli. The findings clarify distinct roles for BIRC2 and BIRC3 in cell signaling, apoptosis regulation, and inflammatory response, offering mechanistic insights relevant to respiratory disease research.

• MG-132 in Hepatocellular Carcinoma: A Translational Perspect

  2026-05-05

  Explore how MG-132, a potent proteasome inhibitor, is shaping hepatocellular carcinoma research by enabling advanced apoptosis assays and cell cycle arrest studies. Uncover unique mechanistic insights, practical assay guidance, and pivotal findings from recent translational studies.

• Paroxetine: Multi-Target Mechanisms and Molecular Insights

  2026-05-04

  This review synthesizes the molecular mechanisms underlying paroxetine’s therapeutic action, emphasizing its selective serotonin reuptake inhibition and emerging multi-target pharmacology. By mapping its interactions with SERT, cytochrome P450 enzymes, and kinase pathways, the study informs both neuropsychiatric and oncology research, highlighting new translational opportunities.

• Pexidartinib (PLX3397): Redefining Macrophage Modulation in

  2026-05-04

  Explore how Pexidartinib (PLX3397) advances tumor microenvironment research through precise macrophage modulation and CSF1R-mediated signaling inhibition. This article offers a unique, evidence-driven perspective on translational assay design using PLX3397.

• pH-Mediated Ribociclib Interactions: QbD Assessment in Cance

  2026-05-03

  This study applies a Quality by Design (QbD) approach to rigorously assess the impact of acid-reducing agents on ribociclib’s solubility and absorption. The findings demonstrate that pH shifts induced by common acid-reducing therapies do not significantly compromise ribociclib’s pharmacokinetic profile, providing clarity for clinical co-administration and setting a benchmark for early-stage drug interaction assessment.

16672 records 1/1112 page Next 12345 下5页 Last page